Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer

Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer

The incidence of ALK gene rearrangement in non-small cell lung cancer (NSCLC) was about 3% to 5%. ALK gene inhibitors have made great breakthrough in recent years, significantly extending the survival period of patients with ALK(+) advanced NSCLC. But the majority of patients will be acquired drug r...

Full description

Bibliographic Details
Main Authors: Peng SONG, Li ZHANG, Congcong SHANG
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2018-09-01
Series:Chinese Journal of Lung Cancer
Subjects:
ALK gene
NSCLC
ALK-TKI
Drug resistance
Detection method
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2018.09.10

Similar Items

Similar Items